{ "items": [ "\n\n
\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur group aims to understand the microRNA-mediated mechanisms fundamental to cardiac fibrosis and electrical remodelling that are associated with atrial fibrillation (a very common rhythm disorder). We are particularly interested in functional cross-talk between two major cell types in the heart \u2013 myocytes and fibroblasts.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nVascular Mechanotransduction in health and disease.
\n \n\n \n \n\n \n\n \n \n \n \n Oxford Centre for Diabetes, Endocrinology and Metabolism\n \n \n\n \n\n\n
\n \n \n \nOur goal is to dissect the molecular mechanisms by which gut hormones, namely GLP-1 and PYY, improve glucose-mediated insulin and glucagon secretion in pancreatic islets. Dysfunction of both secretory processes contributes to the onset of type 2 diabetes and represents the target of effective diabetes intervention.
\n \n\n \n \n\n \n\n \n \n \n \n Oxford Centre for Diabetes, Endocrinology and Metabolism\n \n \n\n \n\n\n
\n \n \n \nWe study cellular physiology of pancreatic islets \u2013 the small organs that regulate the whole-body sugar levels. Our work will help to find new treatments for diabetes \u2013 a disease that is characterised by uncontrolled blood sugar.
\n \n\n \n \n\n \n\n \n \n \n \n Oxford Centre for Diabetes, Endocrinology and Metabolism\n \n \n\n \n\n\n
\n \n \n \nWe investigate the genetic, molecular and physiological basis of endocrine disorders that affect calcium homeostasis, and endocrine tumour development. By identifying and understanding the underlying mechanisms, we aim to establish better diagnostic methods and develop novel targeted therapies for these disorders to improve patient care.
\n \n\n \n \n\n \n\n \n \n \n \n Oxford Centre for Diabetes, Endocrinology and Metabolism\n \n \n\n \n\n\n
\n \n \n \nWe apply an integrated approach to human metabolic disease which involves genetic, genomic, cell biology and whole body metabolic studies to understand the pathogenesis of the complications of obesity such as fatty liver disease, type 2 diabetes and cardiovascular disease.
\n \n\n \n \n\n \n\n \n \n \n \n Oxford Centre for Diabetes, Endocrinology and Metabolism\n \n \n\n \n\n\n
\n \n \n \nWe work to understand how hormones regulate metabolic health in liver, fat and skeletal muscle. Our research has helped to define the role of \u2018pre-receptor\u2019 hormone metabolism in the pathogenesis of metabolic disease and has contributed to the development of novel interventions with the ultimate aim of improving patient care.
\n \n\n \n \n\n \n\n \n \n \n \n Investigative Medicine Division\n \n \n\n \n\n\n
\n \n \n \nWe are focusing on how to make research and innovation relevant to society, sustainable and fair for everyone.
\n \n\n \n \n\n \n\n \n \n \n \n Investigative Medicine Division\n \n \n \n \n MRC Translational Immune Discovery Unit\n \n \n \n \n MRC Weatherall Institute of Molecular Medicine\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Investigative Medicine Division\n \n \n \n \n MRC Translational Immune Discovery Unit\n \n \n \n \n MRC Weatherall Institute of Molecular Medicine\n \n \n\n \n\n\n
\n \n \n \nThe aim of the group is to understand, at the molecular and cellular level, the role of human cutaneous immune responses in mechanisms of disease, treatment and vaccination. We have a particular focus on T cells which recognise inflammatory lipids presented by CD1a. As well as contributing to an understanding of disease pathogenesis, we aim to translate our findings to changes in clinical practice.
\n \n\n \n \n\n \n\n \n \n \n \n Investigative Medicine Division\n \n \n \n \n MRC Translational Immune Discovery Unit\n \n \n \n \n MRC Weatherall Institute of Molecular Medicine\n \n \n\n \n\n\n
\n \n \n \nWe are investigating how iron and anaemia influence immunity and infectious diseases. Our research inspires treatments that control iron physiology to benefit the host at the expense of pathogens.
\n \n\n \n \n\n \n\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nIncreasing and disseminating the evidence-base to improve practice in Transfusion Medicine.
\n \n\n \n \n\n \n\n \n \n \n \n MRC Weatherall Institute of Molecular Medicine\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nWe are using a human genetic approach that relies on the latest developments of Next Generation Sequencing technology to study the intimate relationship that exists between the occurrence of new mutations and the regulation of cell fate choices in the male germline. Because life-long production of sperm is supported by regular divisions of so-called spermatogonial stem cells, each one of us acquire ~30-100 new mutations in our genome, the majority of which is paternal in origin.
\n \n\n \n \n\n \n\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nUnderstanding immune recognition and developing cancer immunotherapy.
\n \n\n \n \n\n \n\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nWe study the molecular mechanisms involved in disease initiation and progression in the myelodysplastic syndromes (MDS) in order to better understand disease pathogenesis and to identify new therapeutic targets and prognostic markers for this disorder.
\n \n\n \n \n\n \n\n \n \n \n \n MRC Molecular Haematology Unit\n \n \n \n \n MRC Weatherall Institute of Molecular Medicine\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nAberrant epigenetic changes are a driving force in many human cancers. The focus of our lab is centred on understanding how epigenetics impacts gene regulation so that this information can potentially be used to develop new therapeutic strategies.
\n \n\n \n \n\n \n\n \n \n \n \n MRC Molecular Haematology Unit\n \n \n \n \n MRC Weatherall Institute of Molecular Medicine\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nWe are interested in the function of the chromatin remodelling factor ATRX and how mutations in this factor lead to human disease.
\n \n\n \n \n\n \n\n \n \n \n \n MRC Molecular Haematology Unit\n \n \n \n \n MRC Weatherall Institute of Molecular Medicine\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nHematopoietic stem cell (HSC) transplantation is the only stem cell therapy in routine clinical use, and it is also the cell type that gives rise to most blood cancers. We use single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.
\n \n\n \n \n\n \n\n \n \n \n \n MRC Weatherall Institute of Molecular Medicine\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nThe ability to sequence whole exomes and genomes of individual people has revolutionised our ability to explore the full spectrum of genetic mutations causing serious human diseases. Working closely with the craniofacial teams based in Oxford and other UK units, we specialise in the application of these methods to children born with a serious malformation of the skull termed craniosynostosis.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur research is devoted to advancing the science of healthcare delivery for management of major cardiovascular conditions and harnessing the power of Big Data to drive change. Large healthcare datasets are being used to create more transparency about healthcare performance and for better risk stratification of populations for more targeted interventions.
\n \n\n \n \n